Tissue Remodeling in Adenomyosis Pathophysiology

Overview

Información sobre este estudio

The aims of this study are to delineate expression of a novel REST-miRNA mediated tissue remodeling pathway in adenomyosis and define its function using novel experimental mouse models, and to delineate REST-miR-137-3p (A) and REST-miR-29b-3p (B) mediators and mechanisms relevant to adenomyosis pathophysiology.

Adenomyosis is a nonmalignant uterine disease characterized by endometrial stroma and glands found within the myometrium.1 Adenomyosis has been associated with heavy and painful menstrual periods, pelvic pain, pain with intercourse, and reproductive dysfunction. However, now that imaging is identifying adenomyosis in younger and more varied women than those electing hysterectomy where pathological diagnosis occurred, many of our assumptions about the clinical disease are changing.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria;

  • Pre-menopausal (21 - 50 years of age).
  • Study group will consist of women seeking hysterectomy for possible adenomyosis adenomyomectomy.
  • Controls will consist of women seeking hysterectomy for uterine prolapse or pelvic pain or transgender men prior to androgen treatment and whose pathology shows a uterus < 100 grams with no evidence of adenomyosis, endometriosis, or leiomyomas.

Exclusion Criteria:

  • No ua\se of GnRH analogues, aromatase inhimitors, selective E2 or P4 receptor modulators, oral contraceptives, or immunotherapy within 3 months prior to surgery in any patient.
  • No history /confirmation or suspicion of autoimmune disease, fibromyalgia, endometriosis, or leiomyomas in any patient.
  • No current or previous history of STDs, pelvic inflammatory disease, endometrial/cervical cancer in any patient.
  • Women who do not exhibit menstrual cycles.

Eligibility last updated 10/21/21. Questions regarding updates should be directed to the study team contact.


 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Elizabeth Stewart, M.D.

Abierto para la inscripción

Contact information:

Maureen Lemens C.C.R.C.

(507) 293-1487

Lemens.Maureen@mayo.edu

More information

Publicaciones

Publications are currently not available